Scientific insight. Strategic direction. Practical execution.

Fulgurite helps biotechnology companies, investors, and pharmaceutical teams make better decisions across discovery and early drug development.

Our support ranges from focused scientific assessments to long-term strategic and operational leadership. Every engagement is adapted to the client’s program, development stage, and internal capabilities.

Program Strategy

We help companies translate promising science into focused, differentiated drug development programs. This begins with selecting the right targets and indications, defining a compelling proof-of-concept, and building a practical path from discovery through preclinical development.

Our support includes:

• Target and indication selection

• Pipeline and portfolio development

• Proof-of-concept development

• Target product profile development

• Program differentiation and positioning

• Translational and biomarker strategy

• Development planning and decision criteria

• Program review, prioritisation, and optimisation

Relevant experience

Fulgurite has built and directed program strategy in indication agnostic settings. We developed a target selection strategy for a cutting-edge discovery platform, increasing the rate of target evaluation fourfold and expanding the company’s pipeline fivefold within nine months.

Our experience also includes leading small-molecule oncology programs, developing integrated discovery strategies, and identifying scientific and developmental risks that could affect program differentiation or progression